Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
Would you consider using steroids in patients with respiratory failure caused by aspiration pneumonitis?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
What is the duration of steroids that you prescribe for organizing pneumonia?
What is your approach to managing ILD associated with inflammatory bowel disease?
How often do you monitor pulmonary function tests in patients with fibrotic lung disease?
